Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...

Roughly 60 000 South Africans die in a year from diseases that are not caused by an infection such as tuberculosis (TB) or ...

Third-quarter results for Medtronic (NYSE:MDT) included a timeline for a planned label expansion for its automated insulin ...

First-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...

Injectable Drug Delivery MarketThe global injectable drug delivery market is estimated to be valued at USD 49.44 billion in ...

The new weight loss drug offers promising results for those who are overweight or obese. Learn about how Zepbound works, its ...

The global injectable drug delivery devices market size is calculated at USD 565 billion in 2025 and is expected to reach around USD 1,217 billion by ...

Roughly 60,000 South Africans die in a year from diseases that are not caused by an infection such as TB or HIV — before they ...

He emphasized that when patients have unpaid bills, prices are raised to offset costs. He claims this is “why healthcare pricing is horrific.” The U.S. healthcare system is both the most expensive and ...